Logo

Microarray Developer NimbleGen Raises $9M in Latest Financing Round

Sep 11, 2001

NEW YORK, Sept 11 – Microarray developer NimbleGen Systems of Madison, Wis., said Tuesday it had raised $9 million in a private round of financing.

The company has raised more than $12.5 million in total.

Investors in the recent round of financing included new investors such as Venture Investors Management, Baird Venture Partners, and State of Wisconsin Investment Board. Previous investors including Skyline Ventures, Tactics II Investments, and The Wisconsin Alumni Research Foundation also participated in the financing round.

NimbleGen produces customized high-density DNA arrays using technology based on digital mirrors. The company said its system is capable of producing specialized arrays in less than four hours.

The company said that it has so far completed the first “pre-manufacturing run” of high-density arrays and that the technology was developing at a “very rapid” pace.

Breaking News
The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.